Incidence and causes for failure of treatment of women with proven osteoporosis

Osteoporosis International

Volumn 16, Issue 11, 2005, Pages 1375-1383

  Zafran, Noah ^a   Liss, Zvi ^a,b   Peled, Ronit ^a,c   Sherf, Michael ^a,b   Reuveni, Haim ^a,d  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c BARZILAI MEDICAL CENTER   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Bisphosphanates; Compliance; Food additives; HRT; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HEALTH SERVICE; HUMAN; INCIDENCE; INTERVIEW; ISRAEL; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POPULATION RESEARCH; PRIORITY JOURNAL; TELEPHONE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CROSS-SECTIONAL STUDIES; DIETARY SUPPLEMENTS; DIPHOSPHONATES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; ISRAEL; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT FAILURE; VITAMIN D;

EID: 27444432134     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-1838-z     Document Type: Article

References (48)

1. Consensus Development Conference on Osteoporosis (1993) Hong Kong, 1-2 April 1993. Am J Med 95:1S-78S
2. Ettinger B, Pressman A, Schein J, Chan C, Silver P, Connolly N (1998) Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patients instructions and discontinuation. J Managed Care Pharm 18:1051-1056
3. Johnell O (1997) The socioeconomic burden of fractures: today and in the 21st century. Am J Med 103:20S-25S, 25S-26S
4. Cole RP, Palushock S, Haboubi (1999) Osteoporosis management: physicians' recommendations and womens' compliance following osteoporosis testing. Women Health 29:101-15
5. Steel SA, Albertazzi P, Howarth EM, Purdie DW (2003) Factors affecting long-term adherence to hormone replacement therapy after screening for osteoporosis. Climacteric 6:96-103
6. Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R (2000) Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2:CD000011.
7. Update in: Cochrane Database Syst Rev 2002(2):CD000011
8. Boyd JR, Covington TR, Stanaszek WF, Coussons RT (1974) Drug defaulting. I. Determinants of compliance. Am J Hosp Pharm 31:362-367
9. Unson CG, Siccion E, Gaztambide J, Gaztambide S, Mahoney Trella P, Prestwood K (2003) Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health 12:1037-1045
10. Fujita T (1996) Clinical guidelines for the treatment of osteoporosis in Japan. Calcif Tissue Int 59 [Suppl 1]:S34-S37
11. Osteoporosis Society of Canada (1996) Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific advisory board, Osteoporosis Society of Canada. Can Med Assoc J 86:1113-1116
12. South-Paul JE (2001) Osteoporosis: part II. Nonpharmacologic and pharmacologic treatment. Am Fam Physician 63:1121-1128
13. Khan A (2003) Advances in osteoporosis therapy. 2003 update of practical guidelines. Can Fam Physician 49:441-447
14. National Institutes of Health (2000) Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 17:1-45
15. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, American Association of Clinical Endocrinologists (2001) American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 7:293-312
16. National Osteoporosis Foundation (1999) Osteoporosis physician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington DC
17. Guideline for osteoporosis treatment (1999) Clalit Health Care Services, Tel Aviv
18. Ministry of Health (1999) Osteoporosis: prevention diagnosis and treatment. A consensus convention. Conducted by the Ministry of Health in Israel, Dec 1999. The Israeli Ministry of Health, Jerusalem
19. Segal E, Tamir A, Ish-Shalom S (2003) Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 5:859-862
20. Wren BG, Brown L (1991) Compliance with hormonal replacement therapy. Maturitas 13:17-21
21. Isolde DT, Bjorn JO (2000) Determinants of long-term HRT and reasons for early discontinuation. Obstet Gynecol 95:507-512
22. Merom D (1998) A national survey of women's health. Israel Center for Disease Control (ICDC), Ministry of Health (unpublished report)
23. Makin M (1987) Osteoporosis and proximal femoral fractures in the female elderly of Jerusalem. Clin Orthop 218:19-23
24. Harris BL, Stergachis A (1990) The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Med Care 28:907-917
25. Soumerai SB, Ross-Degnan D (1991) Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 325:1072-1077
26. Sperber AD, Develis RF, Boehlecke B (1994) Cross-cultural translation, methodology and validation. J Cross-Cultural Psychiatry 25:501-524
27. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. No. 843 of technical reports series. World Health Organization, Geneva
28. Jensen MP, Karoly P, Braver S (1986) The measurement of clinical pain intensity: A comparison of methods. Pain 27:117-126
29. Castel H, Bonneh DY, Sherf M, Liel Y (2001) Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporos Int 12:559-564
30. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965-968; Epub Sep 19 2003
31. Chevalley T, Hoffmeyer P, Bonjour JP, Rizzoli R (2002) An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int 13:450-455
32. Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259-262; Epub 10 Apr 2003
33. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871-1886
34. Lofman O, Larsson L, Toss G (2000) Bone mineral density in diagnosis of osteoporosis: reference population, definition of peak bone mass, and measured site determine prevalence. J Clin Densitom 3:177-186
35. Ballard PA, Purdie DW, Langton CM, Steel SA, Mussurakis S (1998) Prevalence of osteoporosis and related risk factors in UK women in the 7th decade: osteoporosis case finding by clinical referral criteria or predictive model? Osteoporos Int 8:535-539
36. Kirk JK, Spangler JG, Celestino FS (2000) Prevalence of osteoporosis risk factors and treatment among women aged 50 years and older. Pharmacotherapy 20:405-409
37. Krappweis J, Rentsch A, Schwarz UI, Krobot KJ, Kirch W (1999) Outpatient costs of osteoporosis in a national health insurance population. Clin Ther 21:2001-2014
38. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267-276
39. Onder G, Pedone C, Gambassi G, Landi F, Cesari M, Bernabei R (2001) Investigators of the GIFA study. Treatment of osteoporosis among older adults discharged from the hospital in Italy. Eur J Clin Pharmacol 57:599-604
40. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-33
41. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589-1593
42. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047-1059
43. Blumberg G, Kaplan B, Rabinerson D, Goldman GA, Kitai E, Neri A (1996) Women's attitudes towards menopause and hormone replacement therapy. Int J Gynaecol Obstet 54:271-277
44. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA (1999) Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 84:3076-3081
45. The Israeli National Institute for Disease Control (1997) Health status in Israel 1997. Tel Aviv Ministry of Health Publication no. 202
46. Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA (2000) Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 82-A:1063-1070
47. Salzman C (1995) Medication compliance in the elderly. J Clin Psychiatry 56 [Suppl 1]:18-22; discussion 23
48. Johnson RE, Goodman MJ (1997) The impact of increasing patient prescription drug cost sharing on therapeutic classes of drug received and on health status of elderly HMO members. HSR 32:103-122